Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech/Roche blazing new trails with Perjeta, GA101

This article was originally published in Scrip

Executive Summary

While GA101 (obinutuzumab) and Perjeta (pertuzumab) – both from Genentech and its parent company Swiss drug maker Roche – are two different types of medicines targeting different indications, they shared a common bond this week in winning FDA priority reviews just days apart, putting the products on an expedited road to US approval.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts